Edition:
United States

GlaxoSmithKline PLC (GSK.N)

GSK.N on New York Stock Exchange

38.72USD
20 Jan 2017
Change (% chg)

$-0.03 (-0.08%)
Prev Close
$38.75
Open
$38.67
Day's High
$38.75
Day's Low
$38.56
Volume
523,170
Avg. Vol
731,229
52-wk High
$45.58
52-wk Low
$37.20

Select another date:

Thu, Jan 19 2017

UPDATE 2-GSK grabs Astra executive to replace pharma head

* Miels was head of Astra's European business (Adds interview with GSK CEO in Davos, further details)

BRIEF-GlaxoSmithKline appoints Luke Miels President, Global Pharma

* Luke Miels appointed president, global pharmaceuticals, gsk

BRIEF-GSK's pharmaceuticals president Abbas Hussain to leave in 2017

* Abbas hussain, president, global pharmaceuticals has decided to leave company. He has agreed with gsk that he will leave company later this year Source text for Eikon: Further company coverage: (Reporting By UK Bureau)

GSK launches big study to test new injection for HIV prevention

LONDON GlaxoSmithKline said on Tuesday its HIV unit ViiV Healthcare had started a large study to test an experimental long-acting injection for preventing the virus that causes AIDS.

GSK's two-drug HIV therapy shines in two big studies

LONDON GlaxoSmithKline's already fast-growing HIV drug business has received an important boost after two major clinical studies successfully tested a new two-drug treatment regimen to control the virus that causes AIDS.

GSK boosts board-level science as new CEO prepares to take over

LONDON Drugmaker GlaxoSmithKline is bolstering scientific expertise on its board by establishing a new science committee, charged with overseeing research, as a new chief executive prepares to take over.

GSK insider Waterhouse to head drugmaker's HIV unit ViiV

LONDON GlaxoSmithKline said on Monday that Dominique Limet would step down at the end of March 2017 as head of the drugmaker's majority-owned HIV business ViiV Healthcare, to be replaced by GSK insider Deborah Waterhouse.

BRIEF-GlaxoSmithKline submits marketing application for shingles vaccine to EMA

* GSK announces EU regulatory submission of candidate vaccine for prevention of shingles

GSK chases Astra with start of big anemia drug trials

LONDON GlaxoSmithKline has started pivotal trials of an experimental anemia drug, chasing AstraZeneca in the race to develop a medicine that mimics the body's response to high altitude.

GSK chases Astra with start of big anaemia drug trials

LONDON, Nov 24 GlaxoSmithKline has started pivotal trials of an experimental anaemia drug, chasing AstraZeneca in the race to develop a medicine that mimics the body's response to high altitude.

Select another date: